Nautilus Biotechnology (NAUT) EBITDA (2020 - 2021)

Nautilus Biotechnology (NAUT) reported EBITDA of -$1.8 million for Q1 2021, down 209.01% sequentially from -$576035.0 in Q4 2020.

Nautilus Biotechnology (NAUT) EBITDA (2020 - 2021) Analysis & Trends

Nautilus Biotechnology (NAUT) has 2 years of EBITDA data on file, last reported at -$1.8 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-27.75 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	249.90 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-3.72 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	1.14 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	642.90 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-32.68 Mn
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	493.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-445.22 Mn
10	Nautilus Biotechnology	224.14 Mn	224.14 Mn	-	-

Download Data